Clinical experiment designed to assess clinical efficacy targeting N/A in human patients. Primary outcome: cGAMP levels in spinal cord tissue
Analysis of spinal cord tissue samples from ALS patients to measure levels of cyclic GMP-AMP (cGAMP), the specific metabolite produced by cGAS activation. This study aimed to validate the clinical relevance of cGAS/STING pathway activation in human ALS and establish cGAMP as a potential biomarker for mitochondrial DNA release and innate immune activation in ALS patients.
Measurement of cGAMP metabolite levels in post-mortem spinal cord samples from ALS patients compared to controls
Elevated cGAMP levels in ALS patient spinal cord samples
Significantly higher cGAMP levels in ALS patients versus controls
No related hypotheses
No debates yet
No results recorded yet. Use POST /api/experiments/{id}/results to record a result.